Hims & Hers Pulls Copycat Wegovy Pill After FDA, Novo Nordisk Legal Warnings
Hims & Hers has abandoned its copycat Wegovy weight-loss pill after the U.S. Food and Drug Administration opened a probe and threatened enforcement action. The decision follows Novo Nordisk’s legal warnings over patent and trademark infringement, derailing the telehealth provider’s weight-management initiative.
1. Launch of Copycat Weight-Loss Pill
Hims & Hers introduced a semaglutide-based copycat of Wegovy through its digital telehealth platform, aiming to capture share in the burgeoning obesity-treatment market. The product was offered via online consultations and prescription fulfillment directly to consumers.
2. Regulatory and Legal Pushback
The Food and Drug Administration opened an investigation into the unapproved formulation and warned of potential enforcement action, while Novo Nordisk issued legal threats citing patent and trademark infringement. These combined pressures forced Hims & Hers to cease sales immediately.
3. Strategic and Financial Impact
Pulling the weight-loss pill removes a key growth initiative from Hims & Hers’ product lineup and may reduce near-term revenue projections. Market watchers will look for revised guidance and new product strategies to gauge the company’s recovery path.